These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23629442)

  • 1. High-grade lung adenocarcinoma with fetal lung-like morphology: clinicopathologic, immunohistochemical, and molecular analyses of 17 cases.
    Morita S; Yoshida A; Goto A; Ota S; Tsuta K; Yokozawa K; Asamura H; Nakajima J; Takai D; Mori M; Oka T; Tamaru J; Itoyama S; Furuta K; Fukayama M; Tsuda H
    Am J Surg Pathol; 2013 Jun; 37(6):924-32. PubMed ID: 23629442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.
    Suzuki M; Yazawa T; Ota S; Morimoto J; Yoshino I; Yamanaka S; Inayama Y; Kawabata Y; Shimizu Y; Komatsu M; Notohara K; Koda K; Nakatani Y
    Histopathology; 2015 Dec; 67(6):806-16. PubMed ID: 25851923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
    Wang CX; Liu B; Wang YF; Zhang RS; Yu B; Lu ZF; Shi QL; Zhou XJ
    Int J Clin Exp Pathol; 2014; 7(3):1266-74. PubMed ID: 24696747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
    Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
    Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
    Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal gut-like differentiation in gallbladder cancer.
    Koyama K; Maeda D; Tamura D; Narita C; Kudo-Asabe Y; Sato T; Yamamoto Y; Sageshima M; Nanjo H; Goto A
    Hum Pathol; 2017 Dec; 70():27-34. PubMed ID: 28970139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cribriform adenocarcinoma of the lung: clinicopathologic, immunohistochemical, and molecular analysis of 15 cases of a distinctive morphologic subtype of lung adenocarcinoma.
    Mackinnon AC; Luevano A; de Araujo LC; Rao N; Le M; Suster S
    Mod Pathol; 2014 Aug; 27(8):1063-72. PubMed ID: 24390215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphologic, Immunohistochemical, and Genetic Differences Between High-grade and Low-grade Fetal Adenocarcinomas of the Lung.
    Li Y; Xi SY; Yong JJ; Wu XY; Yang XH; Wang F
    Am J Surg Pathol; 2021 Nov; 45(11):1464-1475. PubMed ID: 34138800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis.
    Zhang J; Liang Z; Gao J; Luo Y; Liu T
    Histopathology; 2011 Dec; 59(6):1204-14. PubMed ID: 22175900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical and molecular characterization of clear cell carcinoma of the lung.
    Yousem SA
    Hum Pathol; 2013 Nov; 44(11):2467-74. PubMed ID: 24029707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
    Mansuet-Lupo A; Bobbio A; Blons H; Becht E; Ouakrim H; Didelot A; Charpentier MC; Bain S; Marmey B; Bonjour P; Biton J; Cremer I; Dieu-Nosjean MC; Sautès-Fridman C; Régnard JF; Laurent-Puig P; Alifano M; Damotte D
    Chest; 2014 Sep; 146(3):633-643. PubMed ID: 24676429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary lung adenocarcinoma with morule-like components: a unique histologic hallmark of aggressive behavior and EGFR mutation.
    Tsuta K; Kawago M; Yoshida A; Sekine S; Asamura H; Furuta K; Kushima R
    Lung Cancer; 2014 Jul; 85(1):12-8. PubMed ID: 24768118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.